NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer
July 20(Reuters) - NanoCarrier Co Ltd <4571.T>:Says NanoCarrier entered into a license and collaborative agreement with Orient Europharma Co Ltd <<<4120.TWO>>>(OEP), for co-development of NC-6004 with a new immunotherapy combination drug.This clinical approach will be developed at a global level in regions including United States, Europe and Asian countries(excluding Japan) for head and neck cancer patients building upon the basic agreement dated May 15, 2018.Under the terms of agreement, NanoCarrier grants OEP an exclusive license to develop NC-6004 globally for head and neck cancer, and NanoCarrier will receive a total of $8 million clinical milestone payments.
Latest Key Developments inBiotechnology
- Cyclerion Therapeutics Files For Offering Of Up To 11.55 Mln Shares Of Common Stock By The Selling Stockholders
- Seres Therapeutics Says Board Appointed Marcus Chapman As Principal Financial And Accounting Officer
- Prothena Reports Results From The Phase 3 Vital Amyloidosis Study Of Neod001 In Al Amyloidosis
- Mainstay Medical Says Primary Endpoint Of Reactiv8-B Clinical Trial Was Not Achieved